Kyntra Bio Q2 FY26 returns to profit at $12 million; revenue turns to $(1.5) million
KYNB•Q2 revenue and profit turnaround
Kyntra Bio posted Q2 revenue of $(1.47) million, swinging from $1.35 million a year earlier.
Net income from continuing operations turned to $12 million, or $2.96 per share, from a $13.7 million loss.
Operating loss widened to $17.57 million from $12.05 million, while interest and other income rose to $29.55 million on a $30.94 million gain.
Cash position and clinical pipeline update
Cash, cash equivalents, investments, and accounts receivable totaled $95.7 million at June 30; funding runway projected into 2028.
FG-3246 Phase 2 enrollment continued with interim analysis slated for 4Q 2026; roxadustat Phase 3 in LR-MDS targeted to start 4Q 2026.
